SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Australia reports on PrEP success
Wed Oct 18th - Rapid and high coverage roll-out of PrEP programme can have a dramatic impact on the spread of HIV, Australian researchers report today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

'Old' antibiotic could treat melanoma

Friday October 5th, 2018

An old antibiotic could help to treat melanoma, British researchers have reported.

Scientists from the Medical Research Council (MRC) Institute of Genetics and Molecular Medicine at the University of Edinburgh have found that in mice and in samples from human tumours, nifuroxazide could selectively kill dangerous cells within melanomas.

It is known that many of the more dangerous cells in melanoma tumours produce aldehyde dehydrogenase 1 (ALDH1) and much recent research has focused on blocking the enzyme. However, in this study, published in Cell Chemical Biology, the research team aimed to selectively kill cells producing high ALDH1.

They used nifuroxazide, which is activated by the enzyme ALDH1, which means that it only becomes toxic once it is inside cells producing ALDH1.

The researchers used samples of human melanomas implanted in mice and showed that nifuroxazide killed the tumour cells that produced a lot of ALDH1, without significant toxicity to other cells in the body.

Tumours that develop resistance to BRAF and MEK inhibitors were high in ALDH1, so the team hopes its findings could work alongside BRAF and MEK inhibitors, which are used to treat melanomas.

In the lab, the researchers treated cancer cells lines with BRAF and MEK inhibitors, which increased the number of cells with high levels of ALDH1 and made the cells especially sensitive to nifuroxazide treatment.

Lead researcher Dr Liz Patton, of the MRC Institute for Genetics and Molecular Medicine, said: “There won't be one magic bullet for targeting melanoma - the variations that exist within the cancers mean there will need to be combination therapies.

“When people are given BRAF or MEK drugs to treat melanoma it can result in the tumours having more cells with high levels of ALDH, so we think that's a really important target. We've shown this antibiotic that's used mostly to target intestinal bacteria can also target and kill cancer cells high in the enzyme ALDH1."

Sarvi et al. ALDH1 bio-activates nifuroxazide to eradicate ALDH(High) melanoma-initiating cells. Cell Chemical Biology October 2018

https://doi.org/10.1016/j.chembiol.2018.09.005

Tags: Cancer | Dermatology | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES